Want to see PRLD full AI Analyst Report?
Top Page
Prelude Therapeutics
(NASDAQ:PRLD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.00
▲(104.08% Upside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial performance (continued large losses, negative cash flow, and equity erosion), with mixed technicals providing little momentum support. Corporate events (financing that extends runway and pipeline/leadership progress) are a meaningful positive offset, while valuation remains constrained by lack of profitability and no dividend.
Positive Factors
Clinical pipeline progress
Initiation of a Phase 1 trial and on-track IND/preclinical progress for PRT13722 represent structural de-risking of lead programs. Advancing candidates into clinical and IND stages increases the likelihood of future value inflection, partnership interest, and data-driven go/no-go decisions over the next 2–6 months.
Negative Factors
Sustained negative cash flow
Persistent negative operating and free cash flow indicates the company cannot self-fund development and will remain reliant on external capital until clinical milestones or partnerships convert to recurring revenue. Continued cash burn demands careful runway management and increases fundraising frequency risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline progress
Initiation of a Phase 1 trial and on-track IND/preclinical progress for PRT13722 represent structural de-risking of lead programs. Advancing candidates into clinical and IND stages increases the likelihood of future value inflection, partnership interest, and data-driven go/no-go decisions over the next 2–6 months.
Read all positive factors
Prelude Therapeutics (PRLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$391.06M
Dividend YieldN/A
Average Volume (3M)256.05K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth138.86%
EPS Growth42.14%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding64,917,175
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue14.57
Enterprise Value/Gross Profit14.92
Enterprise Value/Ebitda-3.20
Forecast
1Y Price Target
$8.50Price Target Upside246.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$22.76M
Prelude Therapeutics Business Overview & Revenue Model
Company Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently underg...
How the Company Makes Money
Prelude Therapeutics does not appear to generate material recurring revenue from product sales because it is a clinical-stage company without marketed therapies. Its potential and historical sources of revenue are primarily (1) collaboration and l...
Prelude Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.Positive Updates
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Negative Updates
Potential Competition
The presence of competitors in both JAK2 and KAT6A spaces, including established players like Pfizer, poses a challenge in differentiating Prelude's offerings.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Read all positive updates
Company Guidance
During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.Prelude Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.72M | 12.14M | 7.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.33M | 10.43M | 7.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -76.13M | -97.79M | -125.40M | -120.66M | -114.11M | -110.78M |
| Net Income | -77.80M | -99.50M | -127.17M | -121.83M | -115.44M | -111.69M |
Balance Sheet | ||||||
| Total Assets | 119.64M | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M |
| Cash, Cash Equivalents and Short-Term Investments | 81.55M | 103.21M | 133.61M | 232.94M | 201.73M | 291.23M |
| Total Debt | 17.72M | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M |
| Total Liabilities | 59.46M | 72.68M | 44.06M | 40.58M | 25.06M | 19.20M |
| Stockholders Equity | 60.18M | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M |
Cash Flow | ||||||
| Free Cash Flow | -43.78M | -56.37M | -103.65M | -110.58M | -86.75M | -85.85M |
| Operating Cash Flow | -43.76M | -56.30M | -102.89M | -107.06M | -83.73M | -83.53M |
| Investing Cash Flow | -228.00K | 53.46M | 90.19M | -34.65M | 81.69M | -263.80M |
| Financing Cash Flow | 24.66M | 24.82M | -120.00K | 136.40M | 815.00K | 164.90M |
Prelude Therapeutics Technical Analysis
Positive
2.45
Price Trends
4.39
Positive
3.82
Positive
2.78
Positive
Market Momentum
0.17
Negative
59.40
Neutral
75.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 4.29, below the 50-day MA of 4.39, and below the 200-day MA of 2.78, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 59.40 is Neutral, neither overbought nor oversold. The STOCH value of 75.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRLD.
Prelude Therapeutics Risk Analysis
Prelude Therapeutics disclosed 77 risk factors in its most recent earnings report. Prelude Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prelude Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $84.88M | -3.43 | -201.43% | ― | ― | 33.86% | |
45 Neutral | $66.13M | -0.83 | -68.98% | ― | ― | -26.14% | |
44 Neutral | $391.06M | -4.63 | -118.24% | ― | 138.86% | 42.14% | |
44 Neutral | $28.63M | >-0.01 | -198.48% | ― | -0.46% | 96.28% |
* Healthcare Sector Average
PRLD
Prelude Therapeutics
4.91
4.11
513.75%
PSTV
Plus Therapeutics
4.16
-3.52
-45.83%
PMVP
PMV Pharmaceuticals
1.24
0.14
12.73%
GANX
Gain Therapeutics
1.99
0.35
21.34%
IMMX
Immix Biopharma
9.83
7.42
307.88%
Prelude Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Prelude Therapeutics Shareholders Back Leadership and Governance
Positive
Jun 10, 2026
On June 9, 2026, Prelude Therapeutics held its 2026 Annual Meeting of Stockholders, where shareholders re-elected Class III directors Krishna Vaddi, Paul Scherer, and Katina Dorton to three-year terms expiring at the 2029 annual meeting. Investors...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
Positive
May 12, 2026
Prelude Therapeutics reported first-quarter 2026 results on May 12, 2026, highlighting the start of a Phase 1 trial for PRT12396, its mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, following U.S. regulatory clearance...
Business Operations and StrategyPrivate Placements and Financing
Prelude Therapeutics Prices Public Offering to Extend Runway
Positive
Apr 21, 2026
On April 20, 2026, Prelude Therapeutics announced the pricing of an underwritten public offering of 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants for up to 2,252,252 additional shares at $4.4399 each. The transaction...
Business Operations and StrategyProduct-Related Announcements
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
Positive
Apr 20, 2026
On April 20, 2026, Prelude Therapeutics announced new preclinical data for its lead candidate PRT13722, a first-in-class, orally bioavailable and highly selective KAT6A degrader being developed for HR-positive/HER2-negative breast cancer. The data...
Business Operations and StrategyExecutive/Board Changes
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
Positive
Apr 15, 2026
On April 15, 2026, Prelude Therapeutics announced that veteran oncologist Charles Morris, M.D., will join the company as Executive Vice President and Chief Medical Officer effective April 20, 2026, bringing more than 30 years of oncology drug deve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.